Literature DB >> 19487247

Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10.

Oranun Kerdpin1, Peter I Mackenzie, Kushari Bowalgaha, Moshe Finel, John O Miners.   

Abstract

An N-terminal domain histidine [corresponding to position 39 of UDP-glucuronosyltransferase (UGT) 1A1] is conserved in all UGT1A and UGT2B subfamily proteins except UGT1A4 (Pro-40) and UGT2B10 (Leu-34). Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid). However, only UGT1A4 glucuronidates the tertiary amines lamotrigine (LTG) and trifluoperazine (TFP). In this study, we sought to elucidate the influence of specific N-terminal histidine and proline residues on UGT enzyme substrate selectivity. The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized. Whereas UGT1A1(H39P), UGT1A6(H38P), and UGT1A9(H37P) lacked the ability to metabolize 4MU, 1NP, and naproxen, all glucuronidated LTG. K(m) values for UGT1A1(H39P) and UGT1A9(H37P) were 774 and 3812 microM, respectively, compared with 1579 microM for UGT1A4. UGT1A1(H39P) also glucuronidated TFP with a V(max)/K(m) value comparable to that of UGT1A4. In contrast to the wild-type enzyme, UGT2B10(L34H) glucuronidated 4MU and 1NP with respective K(m) values of 260 and 118 microM. UGT2B7(H35P) lacked activity toward all substrates. The data confirm a pivotal role for an N-terminal domain proline in the glucuronidation of the tertiary amines LTG and TFP by UGT1A subfamily proteins, whereas glucuronidation reactions involving proton abstraction generally, although not invariably, require a histidine at the equivalent position in both UGT1A and UGT2B enzymes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487247     DOI: 10.1124/dmd.109.028225

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

Review 1.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

Review 2.  Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.

Authors:  Dong Dong; Roland Ako; Ming Hu; Baojian Wu
Journal:  Xenobiotica       Date:  2012-03-02       Impact factor: 1.908

3.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

4.  Post-transcriptional Regulation of UGT2B10 Hepatic Expression and Activity by Alternative Splicing.

Authors:  Adrien Labriet; Eric P Allain; Michèle Rouleau; Yannick Audet-Delage; Lyne Villeneuve; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2018-02-09       Impact factor: 3.922

5.  Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.

Authors:  Michael J Osborne; Luciana Coutinho de Oliveira; Laurent Volpon; Hiba Ahmad Zahreddine; Katherine L B Borden
Journal:  J Mol Biol       Date:  2018-11-11       Impact factor: 5.469

Review 6.  The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families.

Authors:  Anna Radominska-Pandya; Stacie M Bratton; Matthew R Redinbo; Michael J Miley
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

Review 7.  The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication.

Authors:  Mohamed Ouzzine; Sandrine Gulberti; Nick Ramalanjaona; Jacques Magdalou; Sylvie Fournel-Gigleux
Journal:  Front Cell Neurosci       Date:  2014-10-28       Impact factor: 5.505

Review 8.  Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases.

Authors:  Ryoichi Fujiwara; Tsuyoshi Yokoi; Miki Nakajima
Journal:  Front Pharmacol       Date:  2016-10-24       Impact factor: 5.810

9.  Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition.

Authors:  Yitian Zhou; Volker M Lauschke
Journal:  Comput Struct Biotechnol J       Date:  2019-12-05       Impact factor: 7.271

10.  A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation.

Authors:  Shannon Robin; Khalil Ben Hassine; Tiago Nava; Chakradhara Rao S Uppugunduri; Marc Ansari; Jayaraman Muthukumaran; Simona Jurkovic Mlakar; Maja Krajinovic
Journal:  BMC Mol Cell Biol       Date:  2022-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.